查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
替代血液替代品市場 - 全球和區域分析：按應用、按最終用途、按產品、按來源、按類型、按成分、按地區 - 分析和預測（2024-2034）
市場調查報告書
商品編碼
1545608

替代血液替代品市場 - 全球和區域分析：按應用、按最終用途、按產品、按來源、按類型、按成分、按地區 - 分析和預測（2024-2034）

Synthetic Blood Substitute Market - A Global and Regional Analysis: Focus on Application, End-use, Product, Source, Type, Configuration, and Region - Analysis and Forecast, 2024-2034
出版日期: | 出版商: BIS Research | 英文 105 Pages | 商品交期: 1-5個工作天內

價格
簡介目錄

人工血液替代的市場規模正快速崛起，作為解決傳統輸血限制的重要解決方案，廣泛應用於全球各個醫療領域。

隨著創傷、手術和慢性疾病的增加，合成血液替代提供了可靠且安全的替代方案，確保重要血液成分的不間斷供應。在樂觀的情況下，2024 年市場價值為 870 萬美元，預計將以 15.43% 的複合年成長率成長，到 2034 年達到 3,670 萬美元。

醫療進步和對可靠血液替代品日益成長的需求正在推動醫療保健領域對替代血液替代品的需求。隨著創傷、手術和慢性病的發生率持續上升，人們越來越需要有效、安全的血液替代來克服傳統輸血的限制。人造血液替代能夠模仿天然血液的攜氧和凝血功能，正成為急診醫學、外科和慢性病管理等應用的重要解決方案。

主要市場統計數據
預測期 2024-2034
2024年評估 870萬美元
2034 年預測 3670萬美元
複合年成長率 15.43%

替代血液替代品市場面臨研發成本高、監管核准複雜等挑戰。此外，確保這些血液替代在不同疾病狀態下的安全性和有效性為市場進入和擴張帶來了額外的複雜性。然而，這些挑戰正在推動生物技術公司、醫療保健提供者和監管機構之間的創新和合作，以加速更先進的合成血液替代的開發，並擴大其在現代醫學中的潛在應用。

以美國為首的北美，在其先進的生物醫學研究部門和發達的醫療基礎設施的推動下，主導著人工血液替代市場。由於研發方面的大力投入和監管機構的大力支持，美國在合成血液替代的開發方面處於領先地位。這種環境促進創新並生產尖端的合成血液產品，滿足創傷治療、手術和慢性病管理的關鍵需求。此外，隨著美國努力改善醫療保健結果並解決血液供不應求，人造血液替代擴大在各個醫療領域被採用。隨著對病人安全和技術進步的關注，美國人工血液替代的有效性和可靠性不斷提高。美國專注於加強醫療保健和滿足日益成長的血液替代需求，鞏固了其在全球人造血液市場領先國家的地位。

該報告調查了全球替代血液替代品市場，並提供了市場概況、應用趨勢、最終用途、產品、原產地、類型、成分、地區和進入市場的公司等。

目錄

執行摘要

第1章市場：產業展望

  • 趨勢：當前和未來的影響評估
  • 供應鏈概覽
  • 研發回顧
  • 監管狀況
  • 相關利益者分析
  • 全球重大事件影響分析
  • 市場動態概覽

第2章 人工血液替代市場（依用途）

  • 應用細分
  • 應用概述
  • 人工血液替代市場（依應用）
  • 人造血液替代市場（依最終用途）

第3章 人工血液替代市場（依產品）

  • 產品細分
  • 產品概述
  • 人工血液替代市場（分產品）
  • 人工血液替代市場（依產地分類）
  • 人工血液替代市場（按類型）
  • 人工血液替代市場（依成分）

第4章 人工血液替代市場（分地區）

  • 人工血液替代市場（按地區）
  • 北美洲
  • 歐洲
  • 亞太地區
  • 其他領域

第5章 公司簡介

  • 未來展望
  • 地理評估
  • 公司簡介
    • Aurum Biosciences
    • HEMARINA
    • Hemoglobin Oxygen Therapeutics LLC
    • KaloCyte, Inc.
    • Spheritech Ltd
    • VisusMed Medical Center
    • OPKO Health, Inc.
    • NuvOx Pharma
    • Prolong Pharmaceuticals
    • Boston Pharmaceuticals
    • ATPL
    • Baxter
    • Biopharma corp
    • NORTHFIELD LABORATORIES INC.
    • Alliance Pharma PLC
    • 其他主要企業

第6章調查方法

簡介目錄
Product Code: BHL2234SA

Introduction to Synthetic Blood Substitute Market

The synthetic blood substitute market is rapidly emerging as a critical solution to address the limitations of traditional blood transfusions, finding widespread applications across various medical fields globally. With increasing incidences of trauma, surgeries, and chronic diseases, synthetic blood substitutes offer a reliable and safe alternative, ensuring an uninterrupted supply of vital blood components. In an optimistic scenario, the market, valued at $8.7 million in 2024, is anticipated to grow at a CAGR of 15.43%, reaching $36.7 million by 2034.

Increasing medical advancements and a growing need for reliable blood alternatives are driving the demand for synthetic blood substitutes in the healthcare sector. As incidences of trauma, surgeries, and chronic diseases continue to rise, there is a growing necessity for effective and safe blood substitutes that can overcome the limitations of traditional blood transfusions. Synthetic blood substitutes, with their ability to mimic the oxygen-carrying and clotting functions of natural blood, have emerged as a critical solution across applications such as emergency medicine, surgeries, and chronic disease management.

KEY MARKET STATISTICS
Forecast Period2024 - 2034
2024 Evaluation$8.7 Million
2034 Forecast$36.7 Million
CAGR15.43%

In the synthetic blood substitute market, challenges include high research and development costs and the complexities associated with regulatory approvals. Additionally, ensuring the safety and efficacy of these substitutes in diverse medical conditions adds further complexity to market entry and expansion. However, these challenges promotes innovation and collaboration among biotech firms, healthcare providers, and regulatory bodies, driving the development of more advanced synthetic blood substitutes and expanding their potential applications in modern medicine.

North America, led by the U.S., dominates the synthetic blood substitute market, driven by its advanced biomedical research sector and substantial healthcare infrastructure. U.S. leads in synthetic blood substitute development due to its robust investment in research and development, coupled with strong support from regulatory bodies. This environment promotes innovation, resulting in cutting-edge synthetic blood products that address critical needs in trauma care, surgeries, and chronic disease management. Furthermore, the U.S. commitment to improving healthcare outcomes and addressing blood supply shortages propels the adoption of synthetic blood substitutes across various medical fields. The nation's emphasis on patient safety and technological advancements ensures that synthetic blood substitutes are continually refined for efficacy and reliability. With a focus on enhancing medical care and meeting the increasing demand for blood substitutes, the U.S. solidifies its position as a key player in the global synthetic blood substitute market.

Key players such as Aurum Biosciences, HEMARINA, Hemoglobin Oxygen Therapeutics LLC, and KaloCyte, Inc. are at the forefront of market expansion, utilizing their technological expertise and strategic partnerships to drive innovation and capture a significant market share. Companies are investing in the construction of new production facilities and the expansion of existing ones to meet the growing demand. For instance, in September 2022, VirTech Bio received approximately $13.7 million in funding from the Pentagon and the U.S. Department of Defense (DoD) to advance the clinical research of its hemoglobin-based oxygen-carrying solution, OxyBridge. This product is designed to prevent hemorrhagic shock in trauma patients and enhance the viability of organs donated for transplantation.

Market Segmentation:

Segmentation 1: by Application

  • Cardiovascular Diseases
  • Malignant Neoplasma
  • Injuries
  • Neonatal Conditions
  • Organ Transplant
  • Maternal Condition
  • Others

Segmentation 2: by End-use

  • Hospitals
  • Ambulatory Surgical Centers
  • Military and Defense
  • Research Laboratories
  • Emergency Services
  • Others

Segmentation 3: by Product

  • Hemoglobin-Based Oxygen Carriers (HBOCs)
  • Perfluorocarbon Emulsions (PFCs)
  • Stem Cell-Derived Red Blood Cells
  • Others

Segmentation 4: by Source

  • Human Blood
  • Microorganism Based Recombinant HB
  • Synthetic Polymers
  • Stem Cells
  • Others

Segmentation 5: by Component

  • Red Blood Cell Substitutes
  • Platelet Substitutes
  • Plasma Substitutes

Segmentation 6: by Configuration

  • Injectable Solutions
  • Powdered Forms
  • Infusion Bags
  • Capsules and Tablets
  • Others

Segmentation 7: by Region

  • North America
  • Europe
  • Asia-Pacific
  • Rest-of-the-World

How can this report add value to an organization?

Product/Innovation Strategy: The global synthetic blood substitute market has been extensively segmented based on various categories, such as application, end-use, product, source, component, and configuration. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Competitive Strategy: A detailed competitive benchmarking of the players operating in the global synthetic blood substitute market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on thorough secondary research, which includes analyzing company coverage, product portfolio, market penetration, and insights gathered from primary experts.

Some of the prominent companies in this market are:

  • Aurum Biosciences
  • HEMARINA
  • Hemoglobin Oxygen Therapeutics LLC
  • KaloCyte, Inc.
  • Spheritech Ltd
  • NuvOx Pharma
  • Prolong Pharmaceuticals
  • Boston Pharmaceuticals

Key Questions Answered in this Report:

  • What are the main factors driving the demand for synthetic blood substitute market?
  • What are the major patents filed by the companies active in synthetic blood substitute market?
  • Who are the key players in the synthetic blood substitute market, and what are their respective market shares?
  • What are the strategies adopted by the key companies to gain a competitive edge in synthetic blood substitute market?
  • What is the futuristic outlook for the synthetic blood substitute market in terms of growth potential?
  • What is the current estimation of the synthetic blood substitute market, and what growth trajectory is projected from 2024 to 2034?
  • Which application, and product segment is expected to lead the market over the forecast period (2024-2034)?
  • Which regions demonstrate the highest adoption rates for synthetic blood substitute market, and what factors contribute to their leadership?

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Key Questions Answered

Analysis and Forecast Note

1. Markets: Industry Outlook

  • 1.1 Trends: Current and Future Impact Assessment
    • 1.1.1 Increasing Demand for Blood Transfusions due to Rising Trauma and Chronic Diseases
    • 1.1.2 Advancement in Stem Cell Technology and Regenerative Medicine
    • 1.1.3 Integration with Advanced Diagnostics and Monitoring
  • 1.2 Supply Chain Overview
    • 1.2.1 Value Chain Analysis
    • 1.2.2 Pricing Forecast
  • 1.3 R&D Review
    • 1.3.1 Patent Filing Trend by Country, by Company
  • 1.4 Regulatory Landscape
  • 1.5 Stakeholder Analysis
    • 1.5.1 Use Case
    • 1.5.2 End User and Buying Criteria
  • 1.6 Impact Analysis for Key Global Events
  • 1.7 Market Dynamics Overview
    • 1.7.1 Market Drivers
    • 1.7.2 Market Restraints
    • 1.7.3 Market Opportunities

2. Synthetic Blood Substitute Market (by Application)

  • 2.1 Application Segmentation
  • 2.2 Application Summary
  • 2.3 Synthetic Blood Substitute Market (by Application)
    • 2.3.1 Cardiovascular Diseases
    • 2.3.2 Malignant Neoplasma
    • 2.3.3 Injuries
    • 2.3.4 Neonatal Conditions
    • 2.3.5 Organ Transplant
    • 2.3.6 Maternal Condition
    • 2.3.7 Others
  • 2.4 Synthetic Blood Substitute Market (by End-use)
    • 2.4.1 Hospitals
    • 2.4.2 Ambulatory Surgical Centers
    • 2.4.3 Military and Defense
    • 2.4.4 Research Laboratories
    • 2.4.5 Emergency Services
    • 2.4.6 Others

3. Synthetic Blood Substitute Market (by Product)

  • 3.1 Product Segmentation
  • 3.2 Product Summary
  • 3.3 Synthetic Blood Substitute Market (by Product)
    • 3.3.1 Hemoglobin-Based Oxygen Carriers (HBOCs)
    • 3.3.2 Perfluorocarbon Emulsions (PFCs)
    • 3.3.3 Stem Cell-Derived Red Blood Cells
    • 3.3.4 Others
  • 3.4 Synthetic Blood Substitute Market (by Source)
    • 3.4.1 Human Blood
    • 3.4.2 Microorganism Based Recombinant HB
    • 3.4.3 Synthetic Polymers
    • 3.4.4 Stem Cells
    • 3.4.5 Others
  • 3.5 Synthetic Blood Substitute Market (by Type)
    • 3.5.1 Red Blood Cell Substitutes
    • 3.5.2 Platelet Substitutes
    • 3.5.3 Plasma Substitutes
  • 3.6 Synthetic Blood Substitute Market (by Configuration)
    • 3.6.1 Injectable Solutions
    • 3.6.2 Powdered Forms
    • 3.6.3 Infusion Bags
    • 3.6.4 Capsules and Tablets
    • 3.6.5 Others

4. Synthetic Blood Substitute Market (by Region)

  • 4.1 Synthetic Blood Substitute Market (by Region)
  • 4.2 North America
    • 4.2.1 Regional Overview
    • 4.2.2 Driving Factors for Market Growth
    • 4.2.3 Factors Challenging the Market
    • 4.2.4 Application
    • 4.2.5 Product
    • 4.2.6 North America Synthetic Blood Substitute Market (by Country)
      • 4.2.6.1 U.S.
        • 4.2.6.1.1 Market by Application
        • 4.2.6.1.2 Market by Product
      • 4.2.6.2 Canada
        • 4.2.6.2.1 Market by Application
        • 4.2.6.2.2 Market by Product
      • 4.2.6.3 Mexico
        • 4.2.6.3.1 Market by Application
        • 4.2.6.3.2 Market by Product
  • 4.3 Europe
    • 4.3.1 Regional Overview
    • 4.3.2 Driving Factors for Market Growth
    • 4.3.3 Factors Challenging the Market
    • 4.3.4 Application
    • 4.3.5 Product
    • 4.3.6 Europe Synthetic Blood Substitute Market (by Country)
      • 4.3.6.1 Germany
        • 4.3.6.1.1 Market by Application
        • 4.3.6.1.2 Market by Product
      • 4.3.6.2 France
        • 4.3.6.2.1 Market by Application
        • 4.3.6.2.2 Market by Product
      • 4.3.6.3 U.K.
        • 4.3.6.3.1 Market by Application
        • 4.3.6.3.2 Market by Product
      • 4.3.6.4 Italy
        • 4.3.6.4.1 Market by Application
        • 4.3.6.4.2 Market by Product
      • 4.3.6.5 Rest-of-Europe
        • 4.3.6.5.1 Market by Application
        • 4.3.6.5.2 Market by Product
  • 4.4 Asia-Pacific
    • 4.4.1 Regional Overview
    • 4.4.2 Driving Factors for Market Growth
    • 4.4.3 Factors Challenging the Market
    • 4.4.4 Application
    • 4.4.5 Product
    • 4.4.6 Asia-Pacific Synthetic Blood Substitute Market (by Country)
      • 4.4.6.1 China
        • 4.4.6.1.1 Market by Application
        • 4.4.6.1.2 Market by Product
      • 4.4.6.2 Japan
        • 4.4.6.2.1 Market by Application
        • 4.4.6.2.2 Market by Product
      • 4.4.6.3 India
        • 4.4.6.3.1 Market by Application
        • 4.4.6.3.2 Market by Product
      • 4.4.6.4 South Korea
        • 4.4.6.4.1 Market by Application
        • 4.4.6.4.2 Market by Product
      • 4.4.6.5 Rest-of-Asia-Pacific
        • 4.4.6.5.1 Market by Application
        • 4.4.6.5.2 Market by Product
  • 4.5 Rest-of-the-World
    • 4.5.1 Regional Overview
    • 4.5.2 Driving Factors for Market Growth
    • 4.5.3 Factors Challenging the Market
    • 4.5.4 Application
    • 4.5.5 Product
    • 4.5.6 Rest-of-the-World Synthetic Blood Substitute Market (by Region)
      • 4.5.6.1 South America
        • 4.5.6.1.1 Market by Application
        • 4.5.6.1.2 Market by Product
      • 4.5.6.2 Middle East and Africa
        • 4.5.6.2.1 Market by Application
        • 4.5.6.2.2 Market by Product

5. Companies Profiled

  • 5.1 Next Frontiers
  • 5.2 Geographic Assessment
  • 5.3 Company Profiles
    • 5.3.1 Aurum Biosciences
      • 5.3.1.1 Overview
      • 5.3.1.2 Top Products/Product Portfolio
      • 5.3.1.3 Top Competitors
      • 5.3.1.4 Target Customers
      • 5.3.1.5 Key Personnel
      • 5.3.1.6 Analyst View
      • 5.3.1.7 Market Share
    • 5.3.2 HEMARINA
      • 5.3.2.1 Overview
      • 5.3.2.2 Top Products/Product Portfolio
      • 5.3.2.3 Top Competitors
      • 5.3.2.4 Target Customers
      • 5.3.2.5 Key Personnel
      • 5.3.2.6 Analyst View
      • 5.3.2.7 Market Share
    • 5.3.3 Hemoglobin Oxygen Therapeutics LLC
      • 5.3.3.1 Overview
      • 5.3.3.2 Top Products/Product Portfolio
      • 5.3.3.3 Top Competitors
      • 5.3.3.4 Target Customers
      • 5.3.3.5 Key Personnel
      • 5.3.3.6 Analyst View
      • 5.3.3.7 Market Share
    • 5.3.4 KaloCyte, Inc.
      • 5.3.4.1 Overview
      • 5.3.4.2 Top Products/Product Portfolio
      • 5.3.4.3 Top Competitors
      • 5.3.4.4 Target Customers
      • 5.3.4.5 Key Personnel
      • 5.3.4.6 Analyst View
      • 5.3.4.7 Market Share
    • 5.3.5 Spheritech Ltd
      • 5.3.5.1 Overview
      • 5.3.5.2 Top Products/Product Portfolio
      • 5.3.5.3 Top Competitors
      • 5.3.5.4 Target Customers
      • 5.3.5.5 Key Personnel
      • 5.3.5.6 Analyst View
      • 5.3.5.7 Market Share
    • 5.3.6 VisusMed Medical Center
      • 5.3.6.1 Overview
      • 5.3.6.2 Top Products/Product Portfolio
      • 5.3.6.3 Top Competitors
      • 5.3.6.4 Target Customers
      • 5.3.6.5 Key Personnel
      • 5.3.6.6 Analyst View
      • 5.3.6.7 Market Share
    • 5.3.7 OPKO Health, Inc.
      • 5.3.7.1 Overview
      • 5.3.7.2 Top Products/Product Portfolio
      • 5.3.7.3 Top Competitors
      • 5.3.7.4 Target Customers
      • 5.3.7.5 Key Personnel
      • 5.3.7.6 Analyst View
      • 5.3.7.7 Market Share
    • 5.3.8 NuvOx Pharma
      • 5.3.8.1 Overview
      • 5.3.8.2 Top Products/Product Portfolio
      • 5.3.8.3 Top Competitors
      • 5.3.8.4 Target Customers
      • 5.3.8.5 Key Personnel
      • 5.3.8.6 Analyst View
      • 5.3.8.7 Market Share
    • 5.3.9 Prolong Pharmaceuticals
      • 5.3.9.1 Overview
      • 5.3.9.2 Top Products/Product Portfolio
      • 5.3.9.3 Top Competitors
      • 5.3.9.4 Target Customers
      • 5.3.9.5 Key Personnel
      • 5.3.9.6 Analyst View
      • 5.3.9.7 Market Share
    • 5.3.10 Boston Pharmaceuticals
      • 5.3.10.1 Overview
      • 5.3.10.2 Top Products/Product Portfolio
      • 5.3.10.3 Top Competitors
      • 5.3.10.4 Target Customers
      • 5.3.10.5 Key Personnel
      • 5.3.10.6 Analyst View
      • 5.3.10.7 Market Share
    • 5.3.11 ATPL
      • 5.3.11.1 Overview
      • 5.3.11.2 Top Products/Product Portfolio
      • 5.3.11.3 Top Competitors
      • 5.3.11.4 Target Customers
      • 5.3.11.5 Key Personnel
      • 5.3.11.6 Analyst View
      • 5.3.11.7 Market Share
    • 5.3.12 Baxter
      • 5.3.12.1 Overview
      • 5.3.12.2 Top Products/Product Portfolio
      • 5.3.12.3 Top Competitors
      • 5.3.12.4 Target Customers
      • 5.3.12.5 Key Personnel
      • 5.3.12.6 Analyst View
      • 5.3.12.7 Market Share
    • 5.3.13 Biopharma corp
      • 5.3.13.1 Overview
      • 5.3.13.2 Top Products/Product Portfolio
      • 5.3.13.3 Top Competitors
      • 5.3.13.4 Target Customers
      • 5.3.13.5 Key Personnel
      • 5.3.13.6 Analyst View
      • 5.3.13.7 Market Share
    • 5.3.14 NORTHFIELD LABORATORIES INC.
      • 5.3.14.1 Overview
      • 5.3.14.2 Top Products/Product Portfolio
      • 5.3.14.3 Top Competitors
      • 5.3.14.4 Target Customers
      • 5.3.14.5 Key Personnel
      • 5.3.14.6 Analyst View
      • 5.3.14.7 Market Share
    • 5.3.15 Alliance Pharma PLC
      • 5.3.15.1 Overview
      • 5.3.15.2 Top Products/Product Portfolio
      • 5.3.15.3 Top Competitors
      • 5.3.15.4 Target Customers
      • 5.3.15.5 Key Personnel
      • 5.3.15.6 Analyst View
      • 5.3.15.7 Market Share
    • 5.3.16 Other Key Companies

6. Research Methodology